Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 1/1/2014 |
| Start Date: | March 2013 |
| End Date: | March 2014 |
Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition
We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a
glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable
of inducing small bowel adaptation and regeneration in patients with short bowel syndrome
(SBS), with the potential to decrease parenteral nutrition dependence.
glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable
of inducing small bowel adaptation and regeneration in patients with short bowel syndrome
(SBS), with the potential to decrease parenteral nutrition dependence.
Patients with short bowel syndrome, between the ages of 18-85 who are dependent on
parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic
Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year.
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
